Neonatal Care
Eat Sleep Console
The Eat Sleep Console (ESC) Model of Care in Obstetric and Neonatal Units across Manitoba standardizes evidence-informed care for newborns exposed to substances and their families to improve health outcomes and the patient/family experience.
A phased implementation is planned for the ESC Model of Care, with HSC, and Women’s Hospital Obstetric and Neonatal Units being implemented in Spring of 2025. Provincial Obstetric and Neonatal sites will be added later at collaboratively determined intervals.
Provincial Clinical Communication: Eat Sleep Console (ESC) Model of Care in Manitoba
Provincial Clinical Guidelines
- Provincial Clinical Guideline – Eat Sleep Console
- Provincial Clinical Guideline – Substance Use & Breastfeeding
Clinical Documents
- Eat Sleep Console (ESC) Assessment Tool
- Eat Sleep Console (ESC) Standard Orders on Postpartum Units
- Eat Sleep Console (ESC) Standard Escalation Orders for NICUs
- Eat Sleep Console (ESC) Standard Weaning Orders for NICUs
Additional Resources
RSV Immunoprophylaxis Program Expansion
Program Overview
As of April 1, 2026, all infants are eligible to receive one dose of nirsevimab during their first RSV season (October 1 to March 31).
- Infants born from October 1 to March 31 should receive nirsevimab in the birthing facility before being discharged.
- Infants born between April 1 and September 30 can receive nirsevimab in the fall.
Providers should plan to offer nirsevimab in October and November to all infants on their roster who were born between April 1 and September 30. These infants will be due for either a 2-, 4- or 6- month appointment in October or November, so nirsevimab can be offered at the same time as other routine childhood vaccines at whichever appointment occurs in October or November. Any providers who are not offering nirsevimab to infants on their roster should still recommend nirsevimab and refer families to public health.
In addition, children with certain high-risk conditions entering their second season may also be eligible in consultation with the Manitoba High-Risk RSV Immunoprophylaxis Program.
Medical clinics that would like to administer nirsevimab to their infant clients and did not already receive an e-mail on how to register, can e-mail: [email protected].
Healthcare Providers
Pediatricians, midwives and family physicians are responsible for obtaining consent and ordering the antibody during hospitalization in the obstetrical units. Medical clinics that would like to administer nirsevimab to their infant clients and did not already receive an e-mail on how to register, can e-mail: [email protected].
Physicians that administer nirsevimab should bill using tariff code 8694: RSV – Respiratory Syncytial Virus Antibody (Paediatric).
Resources
- Expanded Paediatric RSV Immunoprophylaxis Program
- Provincial Clinical Standard
- Manitoba Health RSV Site
- Manitoba Paediatric RSV Immunoprophylaxis Program and Administration Pathways
- Nirsevimab Quick Reference Guide
- Nirsevimab (RSV Antibody) Public Health – Fact Sheet
- Guidance on Nirsevimab Ordering and Allocation
- Manitoba High Risk RSV Program Referral Form
Pharmacy
Pharmacy teams will order the antibody directly from the provincial vaccine warehouse using Manitoba Health Vaccines and Biologics Order Form. Initial orders should occur now, with a second provincial order planned for October.
Resources
Family Engagement
Families will be informed through Public Health campaigns and health care providers.
Resources
Support
If there are any questions or further implementation support required, please contact Amber Douziech, Interim Provincial Director of the Women and Children Provincial Clinical Program and/or Dr. Aaron Chiu of the Manitoba High-Risk RSV Immunoprophylaxis Program [email protected].
Thank you for your continued collaboration in supporting the health of Manitoba’s infants. Your efforts are essential to the successful implementation of this expanded RSV immunoprophylaxis program.